Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-01

Study Completion Date

2017-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety and efficacy of nasal gonadotropins (Menopur) in women undergoing IVF. The purpose of this study is also to report and monitor any and all side effects of the nasal Menopur.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

GnRH Agonist for Luteal Phase Support.

NCT05484193

Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles

UNKNOWN NA

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

NCT04108039

Infertility IVF Preimplantation Diagnosis

COMPLETED NA

The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles

NCT03209687

Infertility

UNKNOWN PHASE4

Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)

NCT00954811

Pregnancy Pregnancy Loss

UNKNOWN PHASE4

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808

Egg Donation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gonadotropins are used during fertility treatments such as intrauterine insemination (IUI) or in vitro fertilization (IVF). These fertility medications are given by injection that contain follicle-stimulating hormone (FSH) alone or combined with luteinizing hormone (LH). During a regularly occurring menstrual cycle, both FSH and LH are produced by the pituitary gland in the brain to naturally stimulate the ovaries to make a single egg each month. When FSH and/or LH are given as an injection as fertility treatment, they work directly on the ovaries to make multiple follicles which are cysts containing the eggs.

Injections of gonadotropins are started early (usually on the third day) in the menstrual cycle to cause multiple eggs to grow to a mature size. Close monitoring of patients with ultrasound and blood are usually needed for monitoring. The ultrasound measures the size of the ovarian follicles. Blood is usually drawn every other day or daily (for a total of 12 days on average) for measurement of Estradiol (E2), progesterone (P4), and luteinizing hormone (LH). The measurement of E2, P4 and LH is intended to quantify the response of the ovaries to the daily injectable gonadotropins. When the follicles grow to a large size (usually 18 mm), human chorionic gonadotropin (hCG), another injectable medication, is then used to trigger the maturity of the eggs before performing egg retrieval during an IVF cycle.

Instead of injectable gonadotropins, this study uses nasal gonadotropins (Menopur) in order to evaluate its safety and efficacy of in women undergoing IVF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional IVF

Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.

Group Type ACTIVE_COMPARATOR

Menopur

Intervention Type DRUG

Nasal versus injectable

Synarel

Intervention Type DRUG

nasal

HCG trigger

Intervention Type DRUG

injectable

Clomiphene citrate

Intervention Type DRUG

oral

Letrozole

Intervention Type DRUG

Oral

IVF protocol using nasal gonadotropins

Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.

Group Type EXPERIMENTAL

Menopur

Intervention Type DRUG

Nasal versus injectable

Synarel

Intervention Type DRUG

nasal

Clomiphene citrate

Intervention Type DRUG

oral

Letrozole

Intervention Type DRUG

Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Menopur

Nasal versus injectable

Intervention Type DRUG

Synarel

nasal

Intervention Type DRUG

HCG trigger

injectable

Intervention Type DRUG

Clomiphene citrate

oral

Intervention Type DRUG

Letrozole

Oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

gonadotropin GnRH agonist HCG Clomid Femara

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age range: 18-45. The participant should be a woman of reproductive age, i.e., premenopausal who is healthy.
2. Body mass index: 19-35 kg/m2
3. Diagnosis of infertility: inability to conceive with unprotected intercourse after 1 year for women aged \< 35 and after 6 months for women aged \> 35.
4. Pap smear within 1 year should be normal.
5. Endometrial cavity will be evaluated and should be normal using hysteroscopy or saline ultrasound
6. Fallopian tubes will be assessed by hysterosalpingogram in women who have normal ovarian reserve, regular menstrual cycles with a partner who has normal semen analysis. Unless there is a clear diagnosis of a reason for infertility, such as poor sperm, poor ovarian reserve, fallopian tube patency will not be performed because it would not change the treatment.
7. Semen analysis will be performed on every male partner to ensure that there are sperm to be used for IVF/ICSI.
8. All assessment will be performed at baseline and before initiation of any treatment.
9. The investigators will obtain at screening Pap smear, hysteroscopy or saline ultrasound, hysterosalpingography, and semen analysis if they have not been done within one year of baseline.

Exclusion Criteria

1. Any medical condition that interferes with the health of the participant such as uncontrolled diabetes, uncontrolled hypertension, cardiac disease, or renal disease.
2. Any type of malignancy.
3. Mental problems that could interfere with the patient's ability to conceive and take care of her baby.
4. Abnormal endometrial cavity that could interfere with implantation and/or carrying the pregnancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes